Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3098742 | 0.85 | EGFR (0.30) | — | |
| SCHEMBL3103561 | 0.80 | CA2 (0.34) | CA2GABRA1GABRB2 | |
| SCHEMBL3093103 | 0.77 | ACHE (0.31) | — | |
| SCHEMBL3105763 | 0.77 | — | — | |
| SCHEMBL15580435 | 0.76 | CA2 (0.46) | CA2GABRA1GABRB2 | |
| SCHEMBL3106123 | 0.74 | AHR (0.50) | — | |
| SCHEMBL3099857 | 0.73 | CA12 (0.34) | CA2 | |
| SCHEMBL25491505 | 0.71 | AHR (0.50) | CA2GABRA1GABRB2 | |
| SCHEMBL3108896 | 0.68 | AHR (0.34) | — | |
| SCHEMBL3100707 | 0.67 | P2RX7 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | claimed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-8338608-B2 | Inhibitors of ion channels | ICAGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1945029-A2 | INHIBITORS OF ION CHANNELS | Icagen, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007056099-A2 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | CA2 169/4885GABRA1 399/4885GABRB2 285/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | CA2 169/4885GABRA1 399/4885GABRB2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.